A Role for the Deubiquitinating Enzyme USP28 in Control of the DNA-Damage Response

Cell

Volumn 126, Issue 3, 2006, Pages 529-542

  Zhang, Dong ^a   Zaugg, Kathrin ^b,c   Mak, Tak W ^b,c   Elledge, Stephen J ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; CLASPIN; ENZYME; P53 BINDING PROTEIN 1; PROTEIN; PROTEIN MDC1; PROTEIN P53; PROTEIN TOPBP1; PUMA PROTEIN; UBIQUITIN SPECIFIC PROTEASE 28; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL LINE; CONTROLLED STUDY; DNA DAMAGE; GENE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN STABILITY; UBIQUITINATION;

EID: 33746766974     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2006.06.039     Document Type: Article

References (47)

1. Ahn J., Urist M., and Prives C. Questioning the role of checkpoint kinase 2 in the p53 DNA damage response. J. Biol. Chem. 278 (2003) 20480-20489
2. Alcasabas A.A., Osborn A.J., Bachant J., Hu F., Werler P.J., Bousset K., Furuya K., Diffley J.F., Carr A.M., and Elledge S.J. Mrc1 transduces signals of DNA replication stress to activate Rad53. Nat. Cell Biol. 3 (2001) 958-965
3. Almog N., Goldfinger N., and Rotter V. p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53. Oncogene 19 (2000) 3395-3403
4. Amerik A.Y., and Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim. Biophys. Acta 1695 (2004) 189-207
5. Aurelio O.N., Kong X.T., Gupta S., and Stanbridge E.J. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol. Cell. Biol. 20 (2000) 770-778
6. Bakkenist C.J., and Kastan M.B. Initiating cellular stress responses. Cell 118 (2004) 9-17
7. Bartek J., and Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3 (2003) 421-429
8. Busino L., Donzelli M., Chiesa M., Guardavaccaro D., Ganoth D., Dorrello N.V., Hershko A., Pagano M., and Draetta G.F. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 426 (2003) 87-91
9. Chen D., Kon N., Li M., Zhang W., Qin J., and Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121 (2005) 1071-1083
10. Chen X., Ko L.J., Jayaraman L., and Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10 (1996) 2438-2451
11. Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., and Wyllie A.H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362 (1993) 849-852
12. Cortez D., Guntuku S., Qin J., and Elledge S.J. ATR and ATRIP: partners in checkpoint signaling. Science 294 (2001) 1713-1716
13. Danial N.N., and Korsmeyer S.J. Cell death: critical control points. Cell 116 (2004) 205-219
14. Falck J., Coates J., and Jackson S.P. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 434 (2005) 605-611
15. Fei P., Bernhard E.J., and El-Deiry W.S. Tissue-specific induction of p53 targets in vivo. Cancer Res. 62 (2002) 7316-7327
16. Garcia-Higuera I., Taniguchi T., Ganesan S., Meyn M.S., Timmers C., Hejna J., Grompe M., and D'Andrea A.D. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7 (2001) 249-262
17. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
18. Herzog K.H., Chong M.J., Kapsetaki M., Morgan J.I., and McKinnon P.J. Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system. Science 280 (1998) 1089-1091
19. Hirao A., Kong Y.Y., Matsuoka S., Wakeham A., Ruland J., Yoshida H., Liu D., Elledge S.J., and Mak T.W. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287 (2000) 1824-1827
20. Hirao A., Cheung A., Duncan G., Girard P.M., Elia A.J., Wakeham A., Okada H., Sarkissian T., Wong J.A., Sakai T., et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol. Cell. Biol. 22 (2002) 6521-6532
21. Jallepalli P.V., Lengauer C., Vogelstein B., and Bunz F. The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J. Biol. Chem. 278 (2003) 20475-20479
22. Jeffers J.R., Parganas E., Lee Y., Yang C., Wang J., Brennan J., MacLean K.H., Han J., Chittenden T., Ihle J.N., et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4 (2003) 321-328
23. Jiang J. Degrading Ci: who is Cul-pable?. Genes Dev. 16 (2002) 2315-2321
24. Jin J., Shirogane T., Xu L., Nalepa G., Qin J., Elledge S.J., and Harper J.W. SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev. 17 (2003) 3062-3074
25. Kannouche P.L., Wing J., and Lehmann A.R. Interaction of human DNA polymerase eta with monoubiquitinated PCNA: a possible mechanism for the polymerase switch in response to DNA damage. Mol. Cell 14 (2004) 491-500
26. Lin S.Y., Li K., Stewart G.S., and Elledge S.J. Human Claspin works with BRCA1 to both positively and negatively regulate cell proliferation. Proc. Natl. Acad. Sci. USA 101 (2004) 6484-6489
27. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., and Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362 (1993) 847-849
28. Manis J.P., Morales J.C., Xia Z., Kutok J.L., Alt F.W., and Carpenter P.B. 53BP1 links DNA damage-response pathways to immunoglobulin heavy chain class-switch recombination. Nat. Immunol. 5 (2004) 481-487
29. McKinney K., Mattia M., Gottifredi V., and Prives C. p53 linear diffusion along DNA requires its C terminus. Mol. Cell 16 (2004) 413-424
30. Rigaut G., Shevchenko A., Rutz B., Wilm M., Mann M., and Seraphin B. A generic protein purification method for protein complex characterization and proteome exploration. Nat. Biotechnol. 17 (1999) 1030-1032
31. Rowan S., Ludwig R.L., Haupt Y., Bates S., Lu X., Oren M., and Vousden K.H. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J. 15 (1996) 827-838
32. Ruffner H., Joazeiro C.A., Hemmati D., Hunter T., and Verma I.M. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc. Natl. Acad. Sci. USA 98 (2001) 5134-5139
33. Scacheri P.C., Rozenblatt-Rosen O., Caplen N.J., Wolfsberg T.G., Umayam L., Lee J.C., Hughes C.M., Shanmugam K.S., Bhattacharjee A., Meyerson M., and Collins F.S. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl. Acad. Sci. USA 101 (2004) 1892-1897
34. Sun Z., Hsiao J., Fay D.S., and Stern D.F. Rad53 FHA domain associated with phosphorylated Rad9 in the DNA damage checkpoint. Science 281 (1998) 272-274
35. Sweeney F.D., Yang F., Chi A., Shabanowitz J., Hunt D.F., and Durocher D. Saccharomyces cerevisiae Rad9 acts as a mec1 adaptor to allow Rad53 activation. Curr. Biol. 15 (2005) 1364-1375
36. Takai H., Naka K., Okada Y., Watanabe M., Harada N., Saito S., Anderson C.W., Appella E., Nakanishi M., Suzuki H., et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J. 21 (2002) 5195-5205
37. Tanaka K., and Russell P. Mrc1 channels the DNA replication arrest signal to checkpoint kinase Cds1. Nat. Cell Biol. 3 (2001) 966-972
38. Valero R., Bayes M., Francisca Sanchez-Font M., Gonzalez-Angulo O., Gonzalez-Duarte R., and Marfany G. Characterization of alternatively spliced products and tissue-specific isoforms of USP28 and USP25. Genome Biol. 2 (2001) RESEARCH0043
39. Vialard J.E., Gilbert C.S., Green C.M., and Lowndes N.F. The budding yeast Rad9 checkpoint protein is subjected to Mec1/Tel1-dependent hyperphosphorylation and interacts with Rad53 after DNA damage. EMBO J. 17 (1998) 5679-5688
40. Villunger A., Michalak E.M., Coultas L., Mullauer F., Bock G., Ausserlechner M.J., Adams J.M., and Strasser A. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302 (2003) 1036-1038
41. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
42. Wang B., Matsuoka S., Carpenter P.B., and Elledge S.J. 53BP1, a mediator of the DNA damage checkpoint. Science 298 (2002) 1435-1438
43. Wang S., Guo M., Ouyang H., Li X., Cordon-Cardo C., Kurimasa A., Chen D.J., Fuks Z., Ling C.C., and Li G.C. The catalytic subunit of DNA-dependent protein kinase selectively regulates p53-dependent apoptosis but not cell-cycle arrest. Proc. Natl. Acad. Sci. USA 97 (2000) 1584-1588
44. Ward I.M., Minn K., van Deursen J., and Chen J. p53 binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol. Cell. Biol. 23 (2003) 2556-2563
45. Ward I.M., Reina-San-Martin B., Olaru A., Minn K., Tamada K., Lau J.S., Cascalho M., Chen L., Nussenzweig A., Livak F., et al. 53BP1 is required for class switch recombination. J. Cell Biol. 165 (2004) 459-464
46. Zhong Q., Gao W., Du F., and Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121 (2005) 1085-1095
47. Zhou B.B., and Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 408 (2000) 433-439